Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.
2020
e19385Background: Pembrolizumab has dramatically improved the survival of patients with non-small cell lung cancer (NSCLC) and is considered the standard of care for first line treatment of NSCLC w...
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI